Market Place
Sourcing Support
All News #Library
Biotech
Janux Announces First Patient Dosed in Phase 1 Study of JANX011
17 Feb 2026 //
BUSINESSWIRE
Janux Pharma Names William Go, M.D., Ph.D., Chief Medical Officer
26 Jan 2026 //
BUSINESSWIRE
Janux Therapeutics Updates Phase 1 JANX008 Study
23 Dec 2025 //
BUSINESSWIRE
Analyst Deems Janux`s Stock Spiral An `Overreaction`
02 Dec 2025 //
FIERCE BIOTECH
Janux Reports Positive Results In Phase 1 Trial Of JANX007
01 Dec 2025 //
BUSINESSWIRE
Janux Pharma Hosts Virtual Event On JANX007 Clinical Data
24 Nov 2025 //
BUSINESSWIRE
Janux Therapeutics Reveals Q3 2025 Financials & Business
06 Nov 2025 //
BUSINESSWIRE
Janux Hits Clinical Milestone in Merck TRACTr Collaboration
05 Aug 2025 //
BUSINESSWIRE
Janux Highlights Bispecific Platform at Virtual R&D Day
24 Jul 2025 //
BUSINESSWIRE
Janux Therapeutics names Janeen Doyle Chief Corporate Officer
15 May 2025 //
BUSINESSWIRE
Janux Therapeutics Begins Phase 1b Expansion with JANX007
05 May 2025 //
BUSINESSWIRE
Janux Reports Q4 & Full-Year 2024 Financial Results
27 Feb 2025 //
BUSINESSWIRE
Janux Doses Selected for Phase 1b Expansion of JANX007 in mCRPC
02 Dec 2024 //
BUSINESSWIRE
Alpine Immune Sciences, Janux said to be looking at possible sales — reports
10 Apr 2024 //
ENDPTS
Janux Announces Safety Data in Escalation Trials for PSMAxCD3-TRACTr JANX007
26 Feb 2024 //
BUSINESSWIRE
Janux Announces Positive Data from Ph 1a Dose Escalation for PSMA-TRACTr JANX007
17 Jul 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.